Navigation Links
Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
Date:1/10/2011

receiving KAPVAY™ discontinued from the pediatric monotherapy study due to adverse reactions.  In the pediatric adjunctive treatment to stimulants study, one patient out of 102 discontinued from KAPVAY™.

"There is a portion of children and adolescents who suffer from symptoms of ADHD who are not responding optimally to current therapies," said Rakesh Jain, MD, MPH, Assistant Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine – Permian Basin, Midland, Texas and Director of Psychiatric Drug Research for R/D Clinical Research at Lake Jackson, Texas, and one of the investigators in the clinical trials.  "The availability of an extended-release formulation of clonidine hydrochloride is an important addition to the current ADHD treatment landscape."

About KAPVAY™

KAPVAY™ (clonidine hydrochloride) extended-release is indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications.  The efficacy of KAPVAY™ in the treatment of ADHD is based on two controlled trials (one monotherapy and one adjunctive to stimulant medication) in children and adolescents ages 6-17 who met DSM-IV criteria for ADHD hyperactive or combined hyperactive/inattentive subtypes.  KAPVAY™ is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social) for patients with this syndrome.  The effectiveness of KAPVAY™ for longer-term use (more than 5 weeks) has not been systemically evaluated in controlled trials.

Administered orally, KAPVAY™ exerts its pharmacological effects as a centrally acting alpha2-adrenoceptor agonist. The formulation in KAPVAY™ is designed to delay the absorption of active drug in order to decrease peak to trough plasma concentration differences.

Important Safety Information

KAPVAY™ s
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
6. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... , December 15, 2014 Investor-Edge ... ZGNX ), Eli Lilly and Company (NYSE: ... Sanofi (NYSE: SNY ), and Novartis AG (NYSE: ... can be accessed at: http://investor-edge.com/register . On ... down 1.16%, the Dow Jones Industrial Average lost 1.79%, to ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... discovery and development company, is pleased to announce the ... United States relating to its GPCR-focused drug ... US significantly strengthens the global patent estate covering Heptares, ... The suite of patents recently granted by the ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory ... for Tuesday, December 9 at 11:00 am ET to Discuss Phase ... , SAN FRANCISCO , Dec. 7 Sunesis ... of new data from two ongoing clinical trials demonstrating that the ...
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
(Date:12/15/2014)... In support of high-quality independent peer ... state laws that may have unintended consequences through ... of public health policy. , The position paper, ... Independent Review, contends that state legislation that restricts ... determinations can result in subpar outcomes for both ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced ... of Quality Assurance. He brings more than 15 ... certifications for manufacturers in the U.S. and abroad. ... Manager at Sonoco Products Company in the Protective Solutions ... Quality Assurance Manager for Prince Industries, all in the ...
(Date:12/15/2014)... Colorado (PRWEB) December 15, 2014 Following ... Friday sales, The Grass Station is gearing up for ... one of Colorado’s oldest and largest marijuana dispensaries, began ... sales event that ran through Thanksgiving weekend. , ... then; people are excited,” says Grass Station CEO and ...
Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Colorado’s Grass Station Helps Holiday Shoppers Put Something Special under the Christmas Tree 2
... for individual women in crisis, but advance access to emergency ... pregnancy. ,Contrary to the fears of critics, ... behavior. ,,According to a new review of studies, ... for emergency contraception had an equal chance of becoming pregnant ...
... what many doctors are not aware of is the fact that ... , The research based on around 250 ... Australia showed that many men; ‘straight and happily married’, do ... up as transmitters of HIV/AIDS to their unsuspecting wives, and non-infected ...
... Clinic researchers have designed a new strategy in the promising ... in boosting T cells -- the immune builders akin to ... strategy may prove to be more successful than methods currently ... which was lost to Hurricane Katrina but recovered at Mayo ...
... called upon MPs to support the newly amended Mental Health ... balance between safeguarding patients’ rights as well as ... for the bill, stating that it will serve to bring ... patients. ,As the bill goes to the House ...
... Children of all ages are exposed to TV commercials for junk foods ... study released by the US Kaiser Family Foundation found that children between ... an average of 21 a day or more than 7,600 per year. ... per day or over 6,000 a year, while children aged two to ...
... As researchers from the University of North Carolina mulled ... //have found out that the rhythmic motion of the ... material from the lungs. ,The research published ... could change existing treatment methods for cystic fibrosis. When ...
Cached Medicine News:Health News:Emergency Contraception Does Not Reduce Unintended Pregnancy Rate 2Health News:Emergency Contraception Does Not Reduce Unintended Pregnancy Rate 3Health News:Sleeping With The Enemy 2Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 2Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 3Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 4Health News:Ever-Controversial Mental Health Act To Be Decided Upon 2
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (2 line, PAN specific-pLDH)...
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
Medicine Products: